PrestonWhiteCampbellIIIMD

EVP Medical Affairs CF Foundation

Dr. Campbell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Vanderbilt University Medical CenterFellowship, Pediatric Pulmonology, 1990 - 1993
Vanderbilt University Medical CenterResidency, Pediatrics, 1980 - 1983
University of Virginia School of MedicineClass of 1980

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

PubMed

576 citations
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation
Frank J. Accurso, Steven M. Rowe, John P. Clancy, Michael P. Boyle, Jordan M. Dunitz
The New England Journal of Medicine. 2010-11-18
407 citations
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation
John P. Clancy, Steven M. Rowe, Frank J. Accurso, Moira L. Aitken, Raouf S. Amin
Thorax. 2012-01-01
719 citations
Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
Lisa Saiman, Bruce C. Marshall, Nicole Mayer-Hamblett, Jane L. Burns, Alexandra L. Quittner
JAMA. 2003-10-01

New Drug Appears to Slow Effects of Cystic Fibrosis, Offering Hope to Long-Suffering PatientsDecember 18th, 2019
Cystic Fibrosis Foundation Statement on FDA Approval of TRIKAFTA, the First Triple-Combination Therapy for the Most Common CF MutationNovember 7th, 2019
Preston W. Campbell, President and CEO of the Cystic Fibrosis Foundation to Retire; Michael P. Boyle, MD, Appointed as Successor Effective January 2020May 21st, 2019